Lilly’s mGlu2/3 Agonist Fails In Phase II For Schizophrenia – But So Does Zyprexa
This article was originally published in The Pink Sheet Daily
Executive Summary
Lilly vows to do another Phase II in effort to replicate an earlier study that showed efficacy for the novel schizophrenia drug over placebo.